Metabolism and nutrition disorders:
Rare (may affect up to 1 in 1,000 people)
Low levels of potassium, calcium, and magnesium in the blood (associated with high doses administered over a prolonged period), loss of appetite, weight loss.
Very rare (may affect up to 1 in 10,000 people)
Low levels of phosphate in the blood (associated with high doses administered over a prolonged period)
Mental disorders:
Very rare (may affect up to 1 in 10,000 people)
Confusion, hallucinations, mental depression
Nervous system disorders:
Rare (may affect up to 1 in 1,000 people)
Damage to peripheral nerves, deterioration or loss of sensitivity
Very rare (may affect up to 1 in 10,000 people)
Organic brain disease, convulsions, blockade of nervous and muscular function, dizziness, balance disorders, headache
Eye disorders:
Very rare (may affect up to 1 in 10,000 people)
Deterioration of vision
Ear and labyrinth disorders:
Very rare (may affect up to 1 in 10,000 people)
Damage to the auditory nerve, hearing loss, Ménière's disease, buzzing/noises in the ears, vertigo
Vascular disorders:
Very rare (may affect up to 1 in 10,000 people)
Decreased blood pressure, increased blood pressure
Gastrointestinal and intestinal disorders:
Rare (may affect up to 1 in 1,000 people)
Vomiting, nausea, increased salivation, inflammation of the mouth
Liver and bile duct disorders:
Rare (may affect up to 1 in 1,000 people)
Elevated liver enzymes and bilirubin in the blood (all reversible)
Skin and subcutaneous tissue disorders:
Uncommon (may affect up to 1 in 100 people)
Allergic skin rash, itching
Rare (may affect up to 1 in 1,000 people)
Redness of the skin
Very rare (may affect up to 1 in 10,000 people)
Hair loss, severe allergic reaction of the skin and mucous membranes accompanied by blisters and redness of the skin (erythema multiforme), which in very severe cases can affect internal organs and may be potentially fatal (Stevens-Johnson syndrome, toxic epidermal necrolysis).
Musculoskeletal, connective tissue, and bone disorders:
Rare (may affect up to 1 in 1,000 people)
Muscle pain (myalgia)
Very rare (may affect up to 1 in 10,000 people)
Muscle tremors (which cause difficulty standing up)
Renal and urinary disorders:
Common (may affect up to 1 in 10 people)
Deterioration of renal function (which generally resolves after discontinuing treatment)
Rare (may affect up to 1 in 1,000 people)
Elevated urea levels in the blood (reversible)
Very rare (may affect up to 1 in 10,000 people)
Acute renal failure and elevated levels of phosphate and amino acids in urine (known as acquired Fanconi syndrome, associated with high doses administered over a prolonged period)
General disorders and administration site conditions:
Rare (may affect up to 1 in 1,000 people)
Increased body temperature
Very rare (may affect up to 1 in 10,000 people)
Pain at the injection site.
The following side effects have also been reported, although their frequency is unknown: The frequencies cannot be estimated from the available data:
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the reach and sight of children.
Do not use this medication after the expiration date that appears on the bottle and on the packaging after CAD. The expiration date is the last day of the month indicated.
This medication does not require special conservation conditions.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This way, you will help protect the environment.
Composition of Genta Gobens 20 mg/ml injectable solution:
– The active ingredient is gentamicin (sulfate). Each vial contains 40 mg of gentamicin (sulfate).
– The other components (excipients) are sodium metabisulfite (E-223), methylparaben (E-218), propylparaben (E-216), sodium hydroxide (E-524) and water for injectable preparations.
Appearance of the product and content of the packaging
The solution contained in the vials of Genta Gobens 20 mg/ml injectable solution is transparent, colorless or slightly yellow. Each package contains 1 vial. Each 2 ml vial contains 40 mg of gentamicin (as sulfate).
Holder of the marketing authorization and responsible for manufacturing
LABORATORIOS NORMON, S.A.
Ronda de Valdecarrizo, 6 – 28760 Tres Cantos – Madrid (SPAIN)
Other presentations:
Genta Gobens 40 mg/ml injectable solution and for perfusion.
Genta Gobens 80 mg/ml injectable solution and for perfusion.
Date of the last review of this leaflet:March 2024.
The detailed and updated information of this medicine is available on the webpage of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.